IXICO plc Appointment of Giulio Cerroni as CEO (2905U)
17 January 2017 - 6:00PM
UK Regulatory
TIDMIXI
RNS Number : 2905U
IXICO plc
17 January 2017
17 January 2017
IXICO plc
("IXICO" or the "Company")
IXICO appoints Giulio Cerroni as Chief Executive Officer
Brings extensive experience in both scaling operations to build
businesses and supplying sophisticated products and services to the
pharmaceutical and research communities
IXICO, the brain health company, today announces that Giulio
Cerroni will be appointed to the Board as Chief Executive Officer
(CEO) with effect from 6 February 2017. Derek Hill, the co-founder
and current CEO, will remain on the board and continue to serve the
Company as an executive director. Derek will have specific
responsibility for deepening the Company's relationships with major
pharmaceutical companies, key opinion leaders and government
agencies as well as advancing IXICO's pioneering range of digital
technologies.
Giulio, aged 55, has almost 30 years of international management
experience gained in life sciences and diagnostics sectors. He was
previously Managing Director of the Genomics division of LGC Group
(LGC), the international life sciences measurement and testing
company. At LGC, he grew divisional revenues threefold and doubled
profits through a combined organic and acquisitive growth strategy
into an organisation with 480 staff based in ten locations
globally. Between April 2015 and August 2016, he led and integrated
three US based acquisitions, significantly enhancing LGC's position
as a leading global genomics tools platform. Previously, Giulio
held a variety of senior roles at Thermo Fisher Scientific, Abgene,
Anachem, ICN Biomedicals and Du Pont. He has a BSc from Cardiff
University and an MBA from Warwick Business School.
Charles Spicer, Non-Executive Chairman of IXICO, commented: "We
are delighted to welcome Giulio to IXICO where he will work with
the executive team to lead the business into its next phase of
growth. Giulio brings extensive experience in both scaling
operations to build businesses and supplying sophisticated products
and services to the pharmaceutical and research communities. On
behalf of the Board, I would like to acknowledge Derek's many
contributions and his vision that has enabled IXICO to establish
itself as a leading company focused on applying innovative digital
technologies to brain health. We look forward to continuing to
build the business together."
Giulio Cerroni added: "I am very excited to be joining IXICO to
lead the Company's next stage of growth towards becoming the global
leader in digital healthcare technologies for the brain health
market. Brain diseases are an area of huge unmet need and provide a
significant growth opportunity for IXICO's digital health
technology platform. In particular, I believe that our scientific
leadership in medical data analysis makes IXICO uniquely placed to
become the global partner of choice to the pharmaceutical industry
as they integrate digital healthcare technologies as part of their
overall product offering."
Additional information:
(i) Giulio Cerroni does not have any current directorship or partnerships
(ii) in the last five years, Giulio Cerroni has been but is no
longer a director or partner of the following companies or
partnerships:
Biosearch Technologies A/S
Biosearch Technologies Inc
Douglas Scientific LLC
(iii) Giulio Cerroni has confirmed that there is no other
additional information to be disclosed under Schedule 2 (g) of the
AIM Rules.
For further information please contact:
IXICO plc
Charles Spicer, Non-Executive Chairman Tel: +44 20
3763 7499
Shore Capital (Nomad and Broker) Tel: +44 20
Bidhi Bhoma / Edward Mansfield 7408 4090
FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway/Mo Noonan/Matthew Moss
About IXICO
IXICO's innovative and proprietary digital healthcare
technologies help those involved in researching and treating
serious diseases to capture and analyse clinical data to make
rapid, informed decisions. In clinical research this includes the
phenotyping of patients, quantification of disease pathology and
measurement of patient outcomes. In clinical practice the mobile
health and digital decision support technologies aid diagnosis,
patient engagement and monitoring. IXICO is also collaborating with
partners to develop companion digital health products targeted at
improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease,
Huntington's disease, multiple sclerosis, Parkinson's disease,
behavioural health, child and adolescent mental health.
More information is available on www.ixico.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAQQLFFDFFEBBK
(END) Dow Jones Newswires
January 17, 2017 02:00 ET (07:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024